Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zenobia Therapeutics has entered into a collaboration agreement with Alzheimer's Drug Discovery Foundation (ADDF).
Subscribe to our email newsletter
Under the agreement, Zenobia will provide ADDF’s researchers with access to its discovery platform including a gene-to-structure platform with in-house cloning, expression and purification in E coli, insect and mammalian cells.
The platform also includes a custom fragment library composed of diverse cores suitable for discovery of lead compounds that cross the blood-brain barrier, fragment screening by multiple validated methods and assay development (enzyme, cell and Drosophila).
In addition, Zenobia will provide access to its internal medicinal chemistry expertise to optimize the fragments to leads that are potent, selective and optimized for CNS ADME/PK properties.
To establish joint research plans, Zenobia will provide complementary consultation to ADDF researchers using its platform as well as assist in preparation of grant proposals.